Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.

Guided by nuclear magnetic resonance (NMR) binding assays and computational docking studies, a series of 5,5' substituted apogossypol derivatives was synthesized that resulted in potent pan-active inhibitors of antiapoptotic Bcl-2 family proteins. Compound 8r inhibits the binding of BH3 peptides to Bcl-X(L), Bcl-2, Mcl-1, and Bfl-1 with IC(50) values of 0.76, 0.32, 0.28, and 0.73 microM, respectively. The compound also potently inhibits cell growth of human lung cancer and BP3 human B-cell lymphoma cell lines with EC(50) values of 0.33 and 0.66 microM, respectively. Compound 8r shows little cytotoxicity against bax(-/-)bak(-/-) cells, indicating that it kills cancers cells via the intended mechanism. The compound also displays in vivo efficacy in transgenic mice in which Bcl-2 is overexpressed in splenic B-cells. Together with its improved chemical, plasma, and microsomal stability relative to compound 2 (apogossypol), compound 8r represents a promising drug lead for the development of novel apoptosis-based therapies for cancer.

[1]  John C Reed,et al.  Bcl-2 family proteins , 1998, Oncogene.

[2]  S. Young,et al.  Synthesis and anti-HIV activity of 1,1'-dideoxygossypol and related compounds. , 1995, Journal of medicinal chemistry.

[3]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J Brickmann,et al.  Texture mapping: a new tool for molecular graphics. , 1994, Journal of Molecular Graphics.

[5]  T. Mitchison,et al.  Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL , 2001, Nature Cell Biology.

[6]  S. Korsmeyer,et al.  Cell Death in Development , 1999, Cell.

[7]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[8]  John Calvin Reed,et al.  Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). , 2006, Blood.

[9]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[10]  John Calvin Reed.  Dysregulation of apoptosis in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Shaomeng Wang,et al.  Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. , 2005, Molecular cancer therapeutics.

[12]  John Calvin Reed,et al.  Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins , 2009, Molecular Cancer Therapeutics.

[13]  M. Pellecchia,et al.  Structure-based discovery of a new class of Bcl-xL antagonists. , 2007, Bioorganic chemistry.

[14]  K. Pienta,et al.  Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa , 2008, Molecular Cancer Therapeutics.

[15]  John Calvin Reed,et al.  Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.

[16]  M. Schuler,et al.  Targeting BCL‐2 family proteins to overcome drug resistance in non‐small cell lung cancer , 2007, International journal of cancer.

[17]  M. Trescol-Biémont,et al.  Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis , 2007, Oncogene.

[18]  John Calvin Reed,et al.  Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists. , 2009, Cancer letters.

[19]  G. Giaccone,et al.  Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non–small cell lung cancer cell line NCI-H460 , 2007, Molecular Cancer Therapeutics.

[20]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[21]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[22]  H. Nishihara,et al.  Direct and selective arylation of tertiary silanes with rhodium catalyst. , 2008, The Journal of organic chemistry.

[23]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[24]  E. Haura,et al.  A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells , 2008, Cancer Chemotherapy and Pharmacology.

[25]  Maurizio Pellecchia,et al.  Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL , 2004 .

[26]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[27]  Shaomeng Wang,et al.  (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. , 2005, Molecular cancer therapeutics.

[28]  Dajun Yang,et al.  Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. , 2003, Biochemical pharmacology.

[29]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[30]  Mary K Joseph,et al.  Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. , 2007, Journal of medicinal chemistry.

[31]  P. Meltzer,et al.  A regioselective route to gossypol analogues: the synthesis of gossypol and 55-didesisopropyl-55-diethylgossypol. , 1985 .

[32]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[33]  H. Abaan,et al.  Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. , 2006, Journal of medicinal chemistry.

[34]  Shaomeng Wang,et al.  Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins. , 2007, Journal of medicinal chemistry.

[35]  J. Downward,et al.  Upregulation of two BH3-only proteins, Bmf and Bim, during TGFβ-induced apoptosis , 2007, Oncogene.